A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis

Sponsor

Myovant Sciences GmbH (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05862272

Collaborator

(none)

1,000

Enrollment

Arm

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

The purpose of this clinical trial to characterize changes in bone mineral density during continuous treatment with relugolix combination tablet for up to 48 months (4 years) and 1 year of post-treatment follow-up in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) or with moderate-to-severe pain associated with endometriosis.

Condition or Disease	Intervention/Treatment	Phase
Uterine Fibroids Endometriosis	Drug: Relugolix Combination Tablet	Phase 3

Detailed Description

A prospective, single-arm, open-label, Phase 3B study to assess the effect of continuous 48 months (4 years) of treatment with relugolix combination tablet (relugolix 40 mg/estradiol [E2] 1 mg/norethindrone acetate [NETA] 0.5 mg) on bone mineral density in premenopausal women with heavy menstrual bleeding associated with uterine leiomyomas (fibroids) and premenopausal women with moderate to severe pain associated with endometriosis.

Approximately 1000 women (500 with heavy menstrual bleeding associated with uterine fibroids and 500 with moderate to severe pain associated with endometriosis) will receive relugolix combination tablet, during which time BMD will be assessed by dual-energy X-ray absorptiometry every 6 months.

A subset of participants will be eligible to enter this study following completion of 1 year of treatment with relugolix combination therapy in MVT-601-050 (NCT04756037; SERENE) and will complete 3 years of treatment under this protocol.

Upon completion of 48 months (4 years) of treatment or after early termination of treatment, participants will enter a 1-year post-treatment follow-up period during which time bone mineral density will be assessed at Month 6 and Month 12 following treatment cessation.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

1000 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase 3B, Single-Arm, Open-Label Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids or Moderate to Severe Pain Associated With Endometriosis

Anticipated Study Start Date :

May 1, 2023

Anticipated Primary Completion Date :

May 1, 2029

Anticipated Study Completion Date :

Aug 1, 2030

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Relugolix Combination Tablet Participants will receive relugolix combination therapy orally once daily for 48 months.	Drug: Relugolix Combination Tablet A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg. Other Names: TAK-385 T-1331285 RVT-601 MVT-601 MVT-601A MYFEMBREE

Arm

Intervention/Treatment

Experimental: Relugolix Combination Tablet

Participants will receive relugolix combination therapy orally once daily for 48 months.

Drug: Relugolix Combination Tablet

A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.

Other Names:

TAK-385

T-1331285

RVT-601

MVT-601

MVT-601A

MYFEMBREE

Outcome Measures

Primary Outcome Measures

Percent change from baseline in BMD (bone mineral density) at Month 48 on-treatment at lumbar spine (L1-L4) in women with uterine fibroids. [Baseline up to Month 48]
Assessed by dual-energy X-ray absorptiometry (DXA) scan.
Percent change from baseline in BMD at Month 48 on-treatment at lumbar spine (L1-L4) in women with endometriosis. [Baseline up to Month 48]
Assessed by dual-energy X-ray absorptiometry (DXA) scan.

Secondary Outcome Measures

Percent change from baseline in BMD at Month 48 on-treatment at total hip and femoral neck in women with uterine fibroids. [Baseline up to Month 48]
Assessed by dual-energy X-ray absorptiometry (DXA) scan.
Percent change from baseline in BMD at Month 48 on-treatment at total hip and femoral neck in women with endometriosis. [Baseline up to Month 48]
Assessed by dual-energy X-ray absorptiometry (DXA) scan.
Percent change from baseline in BMD at Month 6, 12, 18, 24, 30, 36, and 42 on-treatment at the lumbar spine (L1-L4), total hip, and femoral neck in women with uterine fibroids. [Baseline up to Month 6, 12, 18, 24, 30, 36, and 42]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from baseline in BMD at Month 6, 12, 18, 24, 30, 36, and 42 on-treatment at the lumbar spine (L1-L4), total hip, and femoral neck in women with endometriosis. [Baseline up to Month 6, 12, 18, 24, 30, 36, and 42]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from baseline in BMD at Month 48 on-treatment at lumbar spine (L1-L4) in the overall study population. [Baseline up to Month 48]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from baseline in BMD at Month 48 on-treatment at total hip and femoral neck in the overall study population. [Baseline up to Month 48]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from baseline in BMD at Month 6, 12, 18, 24, 30, 36, and 42 on-treatment at the lumbar spine (L1-L4), total hip, and femoral neck in the overall study population. [Baseline up to Month 6, 12, 18, 24, 30, 36, and 42]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from baseline in BMD at post-treatment follow-up (PTFU) Month 6 and PTFU Month 12 at the lumbar spine (L1-L4), total hip, and femoral neck in women with uterine fibroids. [6 months and 12 months post treatment]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from baseline in BMD at PTFU Month 6 and PTFU Month 12 at the lumbar spine (L1-L4), total hip, and femoral neck in women with endometriosis. [6 months and 12 months post treatment]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from last on-treatment BMD measurement to PTFU Month 6 and PTFU Month 12 at the lumbar spine (L1-L4), total hip, and femoral neck in women with uterine fibroids. [6 months and 12 months post treatment]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from last on-treatment BMD measurement to PTFU Month 6 and PTFU Month 12 at the lumbar spine (L1-L4), total hip, and femoral neck in women with endometriosis. [6 months and 12 months post treatment]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from baseline in BMD at PTFU Month 6 and PTFU Month 12 at the lumbar spine (L1-L4), total hip, and femoral neck in the overall study population. [6 months and 12 months post treatment]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Percent change from last on-treatment BMD measurement to PTFU Month 6 and PTFU Month 12 at the lumbar spine (L1-L4), total hip, and femoral neck in the overall study population. [6 months and 12 months post treatment]
Assessed by dual-energy X-ray absorptiometry (DXA) scan at each designated time points.
Incidence of treatment-emergent serious adverse events, and non-serious adverse events leading to treatment discontinuation or withdrawal from the study during the 48 months of treatment. [Baseline up to Month 48]
Safety analyses will be conducted using the safety populations. The treatment-emergent period will be defined as the period of time from the date of the first dose of the study drug through 14 days after the last dose of study drug, or the date of initiation of another investigational agent or hormonal therapy affecting the hypothalamic-pituitary gonadal axis or surgical intervention for uterine fibroids or for endometriosis, whichever occurs first.
Incidence and location of fractures during the 48 months on treatment and 12 months PTFU. [Baseline up to Month 48 and 12 months post treatment]
Safety analyses will be conducted using the safety populations. All adverse events will be coded to preferred term and system organ class using Medical Dictionary for Regulatory Activities (MedDRA) version 24.0 or higher. The incidence of fractures will also be summarized by anatomical sites and whether the fracture qualifies as a fragility fracture. A participant reporting the same adverse event more than once is counted once, and at the maximum severity or strongest relationship to study drug treatment when calculating incidence.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 50 Years

Sexes Eligible for Study:

Female

Accepts Healthy Volunteers:

Key Inclusion Criteria:

Is a premenopausal woman, 18 to 50 years of age (inclusive);
A diagnosis of uterine fibroids confirmed by imaging or review of medical records and reports heavy menstrual bleeding negatively affecting quality of life. or
A diagnosis of endometriosis that is associated with moderate to severe pain.;
If at risk of pregnancy is willing to avoid pregnancy for 4 years (the duration of the treatment period) using nonhormonal methods of contraception.
Has a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at the allocation visit (or Month 12 if entering from MVT-601-050 [NCT04756037; SERENE]);
In good physical and mental health based on medical, surgical, and gynecological history as well as physical, gynecological, and breast examinations, clinical laboratory test results, and vital sign measurements;
Has a body mass index ≥ 18 kg/m^2.

Key Exclusion Criteria:

Has a weight or body habitus that exceeds the limit of the DXA scanner or has a condition that precludes an adequate DXA measurement at the lumbar spine (
Has a DXA result demonstrating the following criteria at any anatomic site (lumbar spine, total hip, femoral neck):

For patients entering de novo a Z-score ≤ -1.5 or T-score ≤ -2.0 (if ≥ 40 years of age)
For patients entering from MVT-601-050 (NCT04756037; SERENE) a 12-month on-treatment DXA demonstrating Z-score ≤ -2.0, T-score ≤ -2.5 (if ≥ 40 years of age), or BMD loss ≥ 8% compared with pre-treatment baseline;

Screening 25-OH vitamin D level < 12 ng/mL (patients with 25-OH vitamin D deficiency with levels ≥ 12 to < 20 ng/mL are permitted if supplementing with vitamin D or if vitamin D supplementation is started in the screening period);
Has a history of or currently has Cushing's Syndrome, Rheumatoid Arthritis, metabolic bone disease, abnormal bone mineral metabolism, , Paget's disease of the bone, collagen vascular disease, Marfan's syndrome, Ehlers-Danlos syndrome, chronic kidney disease (CKD) stage 3 or greater (or glomerular filtration rate (GFR) < 60 mL/min/m2 using Modification of Diet in Renal Disease (MDRD) method), uncorrected hyperparathyroidism, hyperprolactinemia, known pituitary adenoma, hyperthyroidism, anorexia nervosa, bulimia (within the last year),
History of low trauma (fragility) fracture.
Past history of use or current use of medication used to treat bone loss other than calcium and vitamin D preparations;
Prior use of depot-medroxyprogesterone acetate for a treatment period > 2 years (if treatment occurred within the past 5 years) or prior use of GnRH agonist or antagonist for > 12 months total (unless directly entering from MVT-601-050 [NCT04756037; SERENE]);
Malabsorptive disease (including, but not limited to, inflammatory bowel disease and gastric bypass surgery);
Has breast cancer or history of breast cancer
History of organ transplantation or history of bone marrow
BIRADS ≥ 3 Mammogram at entry (or within the past 6 months).
Has a known human immunodeficiency virus (HIV) infection or at high risk of contracting HIV
Has a current psychiatric disorder that would, in the investigator or medical monitor's opinion, impair the ability of the patient to participate in the study or would impair interpretation of their data.